WeaveBio Therapeutics

WeaveBio Therapeutics is pioneering regenerative solutions for hollow organ repair using bioresorbable silk scaffolds developed at a leading Boston university. Our lead programs target urethral strictures and pediatric hypospadias—conditions with no approved alternatives and significant burden in both civilian and veteran populations. With pre-IDE enabling data, FDA feedback, and a scalable GMP-ready process in place, WeaveBio is poised for clinical entry. Our platform has broad applicability across urologic, airway, and transplant-related indications—including ureteral and tracheal strictures—aligning closely with MTEC’s focus on restoring organ function and improving surgical readiness. We are currently raising $11M to support first-in-human studies, pipeline expansion, and strategic collaborations with military and academic partners.